192 related articles for article (PubMed ID: 19937227)
1. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.
Beukelman T; Saag KG; Curtis JR; Kilgore ML; Pisu M
Osteoporos Int; 2010 Sep; 21(9):1573-84. PubMed ID: 19937227
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
[TBL] [Abstract][Full Text] [Related]
7. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
van Staa TP; Geusens P; Zhang B; Leufkens HG; Boonen A; Cooper C
Rheumatology (Oxford); 2007 Mar; 46(3):460-6. PubMed ID: 16899499
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture.
Zarca K; Durand-Zaleski I; Roux C; Souberbielle JC; Schott AM; Thomas T; Fardellone P; Benhamou CL
Osteoporos Int; 2014 Jun; 25(6):1797-806. PubMed ID: 24691648
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
11. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
Moriwaki K; Noto S
Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
Hiligsmann M; Ben Sedrine W; Bruyère O; Reginster JY
Osteoporos Int; 2013 Aug; 24(8):2291-300. PubMed ID: 23371359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]